Coherus Oncology, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Dennis M. Lanfear

Coherus Oncology, Inc.’s own tally for this item (“Elect Director: Dennis M. Lanfear”): 82,524,713 for, 6,482,243 withheld, per its Form 8-K filed June 1, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected by a majority of votes cast each of the Class III director nominees below, Dennis M. Lanfear and Mats L. Wahlström, to the Board of Directors of the Company to hold office until the 2029 annual meeting of stockholders or until their successors are elected.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 11,778,798 for, 148,737 withheld, 9,841 abstained.

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Description as filed by funds: To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected: Mats L. Wahlstrom

Coherus Oncology, Inc.’s own tally for this item (“Elect Director: Mats L. Wahlström”): 81,177,717 for, 7,829,239 withheld, per its Form 8-K filed June 1, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected by a majority of votes cast each of the Class III director nominees below, Dennis M. Lanfear and Mats L. Wahlström, to the Board of Directors of the Company to hold office until the 2029 annual meeting of stockholders or until their successors are elected.”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 10,829,691 for, 1,097,840 withheld, 16 abstained.

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Description as filed by funds: To approve an increase in the number of shares of our common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan.

Coherus Oncology, Inc.’s own tally for this item (“5. An increase in the number of shares of common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan”): 59,507,788 for, 24,853,379 against — passed, per its Form 8-K filed June 1, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an increase in the number of shares of common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan.”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 9,613,299 for, 2,324,065 against, 12 abstained.

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Description as filed by funds: To approve a reduction in the exercise price of certain outstanding stock options.

Coherus Oncology, Inc.’s own tally for this item (“4. The reduction in the exercise price of certain outstanding stock options”): 45,996,610 for, 45,362,110 against — passed, per its Form 8-K filed June 1, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the reduction in the exercise price of certain outstanding stock options.”
Support: 50.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 40 asset managers below reported 260,283 for, 11,629,658 against, 1 abstained.

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

Description as filed by funds: To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).

Coherus Oncology, Inc.’s own tally for this item (“3. A non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote)”): 73,322,772 for, 10,862,168 against — passed, per its Form 8-K filed June 1, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 41 managers: 11,482,449 for, 454,915 against, 12 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 99 managers: 34,921,623 for, 2,414,774 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

Coherus Oncology, Inc.’s own tally for this item (“2. The selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026”): 121,137,511 for, 1,481,497 against — passed, per its Form 8-K filed June 1, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 11,937,369 for, 3 against, 5 abstained.

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.